Chemomab Therapeutics Ltd.
CMMB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $53 | $67 | $58 | $34 |
| Gross Profit | -$53 | -$67 | -$58 | -$34 |
| % Margin | – | – | – | – |
| R&D Expenses | $11 | $18,381 | $16,977 | $6,334 |
| G&A Expenses | $3 | $7,078 | $11,556 | $6,033 |
| SG&A Expenses | $3 | $7,078 | $11,556 | $6,033 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $14,724 | $0 | $0 | $0 |
| Operating Expenses | $14,739 | $25,459 | $28,533 | $12,367 |
| Operating Income | -$14,739 | -$25,459 | -$28,533 | -$12,367 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $794 | $1,238 | $353 | -$111 |
| Pre-Tax Income | -$13,945 | -$24,221 | -$28,180 | -$12,478 |
| Tax Expense | $0 | $0 | -$534 | $0 |
| Net Income | -$13,945 | -$24,221 | -$27,646 | -$12,478 |
| % Margin | – | – | – | – |
| EPS | -3.12 | -8.22 | -9.68 | -4.8 |
| % Growth | 62% | 15.1% | -101.7% | – |
| EPS Diluted | -3.12 | -8.22 | -9.68 | -4.8 |
| Weighted Avg Shares Out | 4,488 | 2,937 | 2,845 | 2,593 |
| Weighted Avg Shares Out Dil | 4,488 | 2,937 | 2,845 | 2,593 |
| Supplemental Information | – | – | – | – |
| Interest Income | $798 | $1,235 | $352 | $0 |
| Interest Expense | $0 | $0 | $353 | $111 |
| Depreciation & Amortization | $53 | $67 | $58 | $34 |
| EBITDA | -$13,958 | -$25,392 | -$28,475 | -$12,333 |
| % Margin | – | – | – | – |